Document is current
Any future updates will be listed below
-
Authors
Graf, Martin R.
Apte, Shruti
Terzo, Esteban
Padhye, Simran
Shi, Shuhao
Cox, Megan K.
Clark, Roger B.
Modur, Vijay
Badarinarayana, Vasudeo https://orcid.org/0000-0003-3593-966X
- License Information
-
More Information
Article History
Received: 7 September 2022
Revised: 20 January 2023
Accepted: 23 January 2023
First Online: 20 February 2023
Declarations
:
: Pharmacokinetic studies were performed at WuXi AppTec Laboratory Testing Division (Cranbury, NJ), which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and compliant with the Office of Laboratory Animal Welfare (OLAW) Assurance to Conduct Public Health Service (PHS)-funded studies. Efficacy studies were conducted at the Crown Biosciences, Loughborough, UK, in compliance with the UK Animals Scientific Procedures Act 1986 (ASPA) and in line with Directive 2010/63/EU of the European Parliament and the Council of September 22, 2010, on the protection of animals used for scientific purposes.
: All authors are employees and shareholders of Eloxx Pharmaceuticals.
